← 返回

瘤内注射编码胞嘧啶脱氨酶-尿嘧啶磷酸核糖转移酶和 IL-15 的工程化 circRNA 可激发优越的抗肿瘤疗效

英文原题:Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy.

查看英文原题

Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy.

PubMed 2026/02/04(内容时间) Mol Cancer Ther Q1 · IF 6.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基因导向酶前药治疗因其低全身毒性而成为一种有前景的抗肿瘤策略。然而,自杀基因递送方面的挑战阻碍了其临床转化。人工工程化的环状RNA(circRNA)与脂质纳米颗粒技术相结合时,展现出卓越的基因递送潜力,具有高稳定性、持久的蛋白编码能力以及成本效益高的生产优势。

我们开发了一种体外合成的circRNA,编码胞嘧啶脱氨酶-尿嘧啶磷酸核糖基转移酶(circCDUPRT)。经瘤内给药后,circCDUPRT实现了持续的瘤内表达,且全身毒性极低。circCDUPRT与前药5-氟胞嘧啶的组合在体外和体内肿瘤模型中均显示出显著的抗肿瘤疗效。在晚期黑色素瘤模型中,将circCDUPRT/5-氟胞嘧啶与表达IL-15的circRNA联合使用,有效增强了CD8+ T细胞和NK细胞的扩增与活化。

总体而言,这些发现确立了合成circRNA平台作为一种成本效益高、高效率的递送系统,适用于基因导向酶前药治疗和免疫治疗应用。

展开英文摘要原文

Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity.

However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production.

We developed an in vitro synthesized circRNA encoding the cytosine deaminase-uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models.

In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15-expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.

论文信息

作者
Niu D、Zhang S、Ma X、Wu Y、Zhu J、Ran J、Shan M、Dai X
单位
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China.China
期刊
Molecular cancer therapeutics2026 Feb 4
原文标识
PubMed 41027739 · DOI 10.1158/1535-7163.MCT-25-0356